Drug intelligence / Profile preview

VB-201 + standard of care

Development stage: Unknown
Lead developer: VBL Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

VB-201 + standard of care is a combination therapy involving VB-201, a first-in-class, orally-available immune modulator, administered alongside standard treatment protocols. VB-201 is designed to modulate the immune system by targeting oxidized phospholipids to regulate and attenuate key immune-inflammatory signaling. The drug acts in a targeted, localized way to modulate the immune system, potentially resulting in better patient outcomes with fewer side effects.

Targets

TLR2 (Toll-like Receptor 2)CD14 (Monocyte differentiation antigen CD14)

Beyond the preview

Go deeper on VB-201 + standard of care.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB-201 + standard of care.

Explore the full profile